Indication
M-protein Related Cardiac Disease
1 clinical trial
1 product
Clinical trial
A Cross-sectional Study on the Efficacy and Safety of the Combination of Daratumumab+Bortezomib+Dexamethasone Regimen and Dapagliflozin in the Treatment of M-protein Related Cardiac DiseaseStatus: Not yet recruiting, Estimated PCD: 2025-01-30